Uni-Bio Science Group Ltd
HKEX:690

Watchlist Manager
Uni-Bio Science Group Ltd Logo
Uni-Bio Science Group Ltd
HKEX:690
Watchlist
Price: 0.108 HKD -4.42%
Market Cap: HK$644.9m

Operating Margin

17%
Current
Improving
by 1.3%
vs 3-y average of 15.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
17%
=
Operating Income
HK$100m
/
Revenue
HK$589.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
17%
=
Operating Income
HK$100m
/
Revenue
HK$589.6m

Peer Comparison

Country Company Market Cap Operating
Margin
HK
Uni-Bio Science Group Ltd
HKEX:690
644.9m HKD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Higher than 82% of companies in Hong Kong
Percentile
82st
Based on 2 973 companies
82st percentile
17%
Low
-36 930 000% — -5.1%
Typical Range
-5.1% — 9.4%
High
9.4% — 8 238.3%
Distribution Statistics
Hong Kong
Min -36 930 000%
30th Percentile -5.1%
Median 2.5%
70th Percentile 9.4%
Max 8 238.3%

Uni-Bio Science Group Ltd
Glance View

Market Cap
644.9m HKD
Industry
Biotechnology

Uni-Bio Science Group Ltd. is an investment holding company with interests in pharmaceutical research and development. The company employs 326 full-time employees The company went IPO on 2001-11-12. The firm operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.

Intrinsic Value
0.167 HKD
Undervaluation 35%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
17%
=
Operating Income
HK$100m
/
Revenue
HK$589.6m
What is Uni-Bio Science Group Ltd's current Operating Margin?

The current Operating Margin for Uni-Bio Science Group Ltd is 17%, which is above its 3-year median of 15.7%.

How has Operating Margin changed over time?

Over the last 3 years, Uni-Bio Science Group Ltd’s Operating Margin has increased from 2.7% to 17%. During this period, it reached a low of 2.7% on Jun 30, 2022 and a high of 20.6% on Jun 30, 2024.

Back to Top